Christopher Dittus is an Oncology physician affiliated with University of North Carolina at Chapel Hill. OpenAlex indexes 76 publications with 1,406 citations (h-index 14); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
170 Manning Drive 3rd Floor Campus Box 7305
Chapel Hill, NC 275996287
Telephone
984-974-0000Registry record last updated 14 Sept 2017.
Clinical trials
- Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Sponsor: UNC Lineberger Comprehensive Cancer Center
- A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
Sponsor: UNC Lineberger Comprehensive Cancer Center
- BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
Sponsor: UNC Lineberger Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20252 payments
- Genmab U.S., Inc.Program year20241 payment
- ADC Therapeutics America, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
35.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor23.3%Valacyclovir100%Part D≥16 patientsShort-acting sulfonamides7%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
35.2%Kinase inhibitor18.1%Brukinsa73%Jaypirca27%Part D<11 patientsThalidomide Analog17.1%Revlimid57%Lenalidomide43%Part D<11 patientsNervous system
18.8%Gabapentinoids13.2%Gabapentin100%Part D<11 patientsPhenothiazine5.6%Prochlorperazine Maleate100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical and Electrodiagnostic Findings in Anti-myelin–Associated Glycoprotein Antibody Polyneuropathy: A Single Center Review
Journal of Clinical Neuromuscular Disease
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Carey, MD
University of North Carolina at Chapel Hill
Robert Sandler, MD
University of North Carolina at Chapel Hill
Diana Perkins, MD
University of North Carolina at Chapel Hill
Hyman Muss, MD
University of North Carolina at Chapel Hill
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”